eBulletin Newsletter

NCCN Flash Updates: NCCN Guidelines and NCCN Templates Updated

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for and the NCCN Drugs and Biologics Compendium (NCCN Compendium^®) Chronic Myeloid Leukemia. These NCCN Guidelines^® are currently available as Version 2.2022.

Link directly to the Updates section of the NCCN Guidelines:
Chronic Myeloid Leukemia

• Treatment Recommendations Based on BCR-ABL1 Mutation Profile (CML-5)
  • Asciminib added to the Table for Treatment Recommendations Based on BCR-ABL1 Mutation Profile
  • Footnote x added: Asciminib is a treatment option for CP-CML patients with the T315I mutation and/or CP-CML with resistance or intolerance to at least two prior TKIs.
• Management of Ponatinib Toxicity (CML-G 6 of 9)
  • Bullet one modified: Vascular occlusion: Arterial and venous thrombosis and occlusions, including fatal myocardial infarction and stroke, have occurred at a considerable rate Arterial occlusive events (AOEs; including fatal myocardial infarction and stroke) and venous thromboembolic events (VTEs), have occurred in patients treated with ponatinib.
• Management of Asciminib Toxicity (CML-G 7 of 9) 
  • New page added for the Management of Asciminib Toxicity

NCCN has published updates to the NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease. These NCCN Guidelines are currently available as Version 3.2021. 

Link directly to the Updates section of the NCCN Guidelines:
Cancer-Associated Venous Thromboembolic Disease

• The Discussion section has been updated to reflect changes in the algorithm. (MS-1)

NCCN has published updates to the NCCN Chemotherapy Order Templates (NCCN Templates^®) for T-cell Large Granular Lymphocytic Leukemia to reflect the currently published NCCN Guidelines for T-Cell Lymphomas v1.2021

• The following NEW NCCN templates have been published:
  • LGLL1: Low-dose Methotrexate
  • LGLL2: Low-dose Methotrexate/PredniSONE
  • LGLL3: Oral Cyclophosphamide
  • LGLL4: Oral Cyclophosphamide/PredniSONE
  • LGLL5: CycloSPORINE
  • LGLL6: Pentostatin
  • LGLL7: Cladribine
  • LGLL8: Fludarabine
  • LGLL9: Alemtuzumab
  • LGLL10: CycloSPORINE/PredniSONE

NCCN has published updates to the NCCN Templates^® for T-cell Prolymphocytic Leukemia to reflect the currently published NCCN Guidelines for T-Cell Lymphomas v1.2021

• The following NEW NCCN templates have been published:
  • TPLL1: Alemtuzumab
  • TPLL2: FMC (Fludarabine/MitoXANTRONE/Cyclophosphamide) + Alemtuzumab
  • TPLL3: Pentostatin + Alemtuzumab

NCCN has published updates to the NCCN Templates for Prostate Cancer to reflect the currently published NCCN Guidelines for Prostate Cancer v1.2022.

• The following New NCCN Template has been published
  • PRO29: Leuprolide Mesylate
• The Title has been updated on the following NCCN Templates:
  • PRO15: Leuprolide Acetate
  • PRO27: CABAZItaxel/CARBOplatin/PredniSONE
• Changes to the Indication section have been made on the following templates:
  • PRO8: Abiraterone/PredniSONE or MethylPREDNISolone
  • PRO12: Pembrolizumab
  • PRO27: CABAZItaxel/CARBOplatin/PredniSONE
• References have been updated on the following templates:
  • PRO5: MitoXANTRONE/PredniSONE
  • PRO8: Abiraterone/PredniSONE or MethylPREDNISolone
• Changes to the Chemotherapy Regimen section have been made on the following templates:
  • PRO8: Abiraterone/PredniSONE or MethylPREDNISolone
  • PRO9: Enzalutamide
  • PRO10: DOCEtaxel
  • PRO13: Goserelin
  • PRO14: Histrelin
  • PRO15: Leuprolide Acetate
  • PRO16: Triptorelin
  • PRO17: Degarelix
  • PRO18: Nilutamide
  • PRO19: Flutamide
  • PRO20: Bicalutamide
  • PRO21: Apalutamide
  • PRO22: Darolutamide
  • PRO27: CABAZItaxel/CARBOplatin/PredniSONE
  • PRO28: Relugolix
• Drug information notes for the following agents have been updated in the Supportive Care, Monitoring and Hold Parameters, and/or Safety Parameters and Special Instructions sections:
  • Apalutamide
  • Bicalutamide
  • Dexamethasone
  • Flutamide
  • Goserelin
  • Histrelin
  • Leuprolide Acetate
  • MitoXANTRONE
  • Nilutamide
  • Pembrolizumab
  • Relugolix
  • Triptorelin

For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Drugs & Biologics Compendium (NCCN Compendium^®), the NCCN Biomarkers Compendium^®, the NCCN Chemotherapy Order Templates (NCCN Templates^®), the NCCN Radiation Therapy Compendium™, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.

To view the NCCN Guidelines for Patients^®, please visit NCCN.org/patientguidelines.

Free NCCN Guidelines apps for iPhone, iPad, and Android devices are now available! Visit NCCN.org/apps.

About NCCN Flash Updates™

NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium^®, and other NCCN Content.

Subscribe to NCCN Flash Updates™

Please note: 1. Third Party Content. The NCCN Content may contain content (such as figures, tables or illustrations) that NCCN licenses from third parties as displayed on NCCN Third Party Content FTP site: ftp://ftp1.nccn.org (To access: user name:content; password is NCCNcontent) (“Third Party Content”). Licensee shall be solely responsible for obtaining permissions from each such third party to use any such Third Party Content in the Permitted Works.

Access information on permissions and licensing of NCCN Content

Users may unsubscribe from Flash Updates at any time contacting us. NOTE: The subscription fee for NCCN Flash Updates™ is non-refundable.